Literature DB >> 8656025

Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells.

M L Frazier1, E Fernández, R de Llorens, N M Brown, S Pathak, K R Cleary, J L Abbruzzese, K Berry, M Olive, A Le Maistre, D B Evans.   

Abstract

CONCLUSION: We established a new human pancreatic adenocarcinoma cell line, MDAPanc-28. Studies on this new line indicate that it expressed both acinar and ductal gene products suggesting that the patterns of gene expression in the pancreatic adenocarcinoma from which this cell line arose have features similar to those of the protodifferentiated cells hypothesized by Rutter and his colleagues for the developing pancreas (1,2).
BACKGROUND: The cell line arose from a tumor that, like most pancreatic adenocarcinomas, was ductal on the basis of its histological appearance.
METHODS: Once the cell line was established in culture, they were subjected to cytogenetic analysis and tested for their ability to grow in nude mice. RNA from the cells was analyzed by Northern blot analysis and PCR of reverse transcribed cDNA for the expression of both acinar and duct cell gene products. DNA was analyzed for the presence of mutated K-ras at codon 12.
RESULTS: The cell line expressed trypsin and ribonuclease RNA, which are considered to be acinar cell markers, and carbonic anhydrase II (CAII), which is considered to be a duct-cell markers. The histological appearance of xenografts in nude mice was similar to that of the tumor from which the cell line was established. The chromosome number varied between 46 and 60.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8656025     DOI: 10.1007/BF02788373

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  13 in total

1.  Cancer of the pancreas (nonendocrine): a suggested morphologic classification.

Authors:  A L Cubilla; P J Fitzgerald
Journal:  Semin Oncol       Date:  1979-09       Impact factor: 4.929

2.  Expression of acinar and ductal products in Capan-1 cells growing in synthetic serum and serum-free media.

Authors:  E Fernández; M J Fallon; M L Frazier; R de Llorens; C M Cuchillo
Journal:  Cancer       Date:  1994-05-01       Impact factor: 6.860

3.  Regulation of specific protein synthesis in cytodifferentiation.

Authors:  W J Rutter; J D Kemp; W S Bradshaw; W R Clark; R A Ronzio; T G Sanders
Journal:  J Cell Physiol       Date:  1968-10       Impact factor: 6.384

4.  Cell lineage markers in human pancreatic cancer.

Authors:  J H Kim; S B Ho; C K Montgomery; Y S Kim
Journal:  Cancer       Date:  1990-11-15       Impact factor: 6.860

5.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

6.  Immunohistochemical localization of carbonic anhydrase isoenzymes in the human pancreas.

Authors:  T Kumpulainen; P Jalovaara
Journal:  Gastroenterology       Date:  1981-04       Impact factor: 22.682

7.  Chromosome banding techniques.

Authors:  S Pathak
Journal:  J Reprod Med       Date:  1976-07       Impact factor: 0.142

8.  Identification of procollagen mRNAs transferred to diazobenzyloxymethyl paper from formaldehyde agarose gels.

Authors:  N Rave; R Crkvenjakov; H Boedtker
Journal:  Nucleic Acids Res       Date:  1979-08-10       Impact factor: 16.971

9.  Insulin gene expression during development of the fetal bovine pancreas.

Authors:  M L Frazier; R A Montagna; G F Saunders
Journal:  Biochemistry       Date:  1981-01-20       Impact factor: 3.162

10.  Efficient extraction of RNA from mammalian tissue.

Authors:  M L Frazier; W Mars; D L Florine; R A Montagna; G F Saunders
Journal:  Mol Cell Biochem       Date:  1983       Impact factor: 3.396

View more
  8 in total

1.  Role of sialyltransferases involved in the biosynthesis of Lewis antigens in human pancreatic tumour cells.

Authors:  Rosa Peracaula; Glòria Tabarés; Anna López-Ferrer; Reinhard Brossmer; Carme de Bolós; Rafael de Llorens
Journal:  Glycoconj J       Date:  2005-03       Impact factor: 2.916

2.  NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity.

Authors:  Shuichi Fujioka; Jiangong Niu; Christian Schmidt; Guido M Sclabas; Bailu Peng; Tadashi Uwagawa; Zhongkui Li; Douglas B Evans; James L Abbruzzese; Paul J Chiao
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

3.  Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Zhen Fan; Douglas B Evans; Paul J Chiao
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

4.  Effect of innate glutathione levels on activity of redox-responsive gene delivery vectors.

Authors:  Devika S Manickam; Jing Li; David A Putt; Qing-Hui Zhou; Chao Wu; Lawrence H Lash; David Oupický
Journal:  J Control Release       Date:  2009-08-29       Impact factor: 9.776

5.  Frankincense essential oil prepared from hydrodistillation of Boswellia sacra gum resins induces human pancreatic cancer cell death in cultures and in a xenograft murine model.

Authors:  Xiao Ni; Mahmoud M Suhail; Qing Yang; Amy Cao; Kar-Ming Fung; Russell G Postier; Cole Woolley; Gary Young; Jingzhe Zhang; Hsueh-Kung Lin
Journal:  BMC Complement Altern Med       Date:  2012-12-13       Impact factor: 3.659

6.  Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.

Authors:  James A McCubrey; Akshaya K Meher; Shaw M Akula; Stephen L Abrams; Linda S Steelman; Michelle M LaHair; Richard A Franklin; Alberto M Martelli; Stefano Ratti; Lucio Cocco; Fulvio Barbaro; Przemysław Duda; Agnieszka Gizak
Journal:  Aging (Albany NY)       Date:  2022-04-27       Impact factor: 5.682

7.  Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.

Authors:  Stephen L Abrams; Przemysław Duda; Shaw M Akula; Linda S Steelman; Matilde L Follo; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Giuseppe Montalto; Maria Rita Emma; Melchiorre Cervello; Dariusz Rakus; Agnieszka Gizak; James A McCubrey
Journal:  Cells       Date:  2022-02-24       Impact factor: 7.666

8.  APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells.

Authors:  James Andrew McCubrey; Stephen L Abrams; Linda S Steelman; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Paolo Lombardi; Agnieszka Gizak; Przemysław Duda
Journal:  Biomolecules       Date:  2022-02-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.